Innate Pharma (IPHA) Equity Ratio (2017 - 2019)

Innate Pharma (IPHA) has disclosed Equity Ratio for 3 consecutive years, with 0.54 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Equity Ratio rose 46.15% year-over-year to 0.54, compared with a TTM value of 0.54 through Dec 2019, up 46.15%, and an annual FY2019 reading of 0.54, up 46.15% over the prior year.
  • Equity Ratio was 0.54 for Q4 2019 at Innate Pharma, up from 0.37 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.54 in Q4 2019 and bottomed at 0.34 in Q4 2017.
  • Average Equity Ratio over 3 years is 0.42, with a median of 0.37 recorded in 2018.
  • The sharpest move saw Equity Ratio rose 9.97% in 2018, then surged 46.15% in 2019.
  • Year by year, Equity Ratio stood at 0.34 in 2017, then rose by 9.97% to 0.37 in 2018, then skyrocketed by 46.15% to 0.54 in 2019.
  • Business Quant data shows Equity Ratio for IPHA at 0.54 in Q4 2019, 0.37 in Q4 2018, and 0.34 in Q4 2017.